| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $1,348,474 ) |
| | 2025 | 2025 | MARKER THERAPEUTICS INC | 2450 HOLCOMBE BLVD STE BCM-A | HOUSTON | TX | 77021-2039 | HARRIS | USA | R44CA287653 | Controlling Tumor Immune Escape in Pancreatic Cancer using a Dual T Cell Product Strategy | 001 | 2 | NIH | 5/7/2025 | $1,348,474 |
| | 2025 | 2024 | MARKER THERAPEUTICS INC | 2450 HOLCOMBE BLVD STE BCM-A | HOUSTON | TX | 77021-2039 | HARRIS | USA | R44CA285177 | Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant | 000 | 2 | NIH | 10/31/2024 | $0 |
| | 2025 | 2024 | MARKER THERAPEUTICS INC | 2450 HOLCOMBE BLVD STE BCM-A | HOUSTON | TX | 77021-2039 | HARRIS | USA | R44CA287653 | Controlling Tumor Immune Escape in Pancreatic Cancer using a Dual T Cell Product Strategy | 000 | 1 | NIH | 4/11/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $3,174,534 ) |
| | 2024 | 2024 | MARKER THERAPEUTICS INC | 9350 KIRBY DR STE 300 | HOUSTON | TX | 77054-2528 | HARRIS | USA | R44CA291521 | A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin Lymphoma | 000 | 1 | NIH | 8/8/2024 | $665,000 |
| | 2024 | 2024 | MARKER THERAPEUTICS INC | 9350 KIRBY DR STE 300 | HOUSTON | TX | 77054-2528 | HARRIS | USA | R01FD007272 | Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in AML Patients following Allogeneic Stem Cell Transplant with Minimal Residual Disease | 002 | 2 | FDA | 2/21/2024 | $519,750 |
| | 2024 | 2024 | MARKER THERAPEUTICS INC | 9350 KIRBY DR STE 300 | HOUSTON | TX | 77054-2528 | HARRIS | USA | R44CA291521 | A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin Lymphoma | 001 | 1 | NIH | 8/26/2024 | $0 |
| | 2024 | 2024 | MARKER THERAPEUTICS INC | 9350 KIRBY DR STE 300 | HOUSTON | TX | 77054-2528 | HARRIS | USA | R44CA287653 | Controlling Tumor Immune Escape in Pancreatic Cancer using a Dual T Cell Product Strategy | 000 | 1 | NIH | 6/14/2024 | $650,671 |
| | 2024 | 2024 | MARKER THERAPEUTICS INC | 9350 KIRBY DR STE 300 | HOUSTON | TX | 77054-2528 | HARRIS | USA | R44CA285177 | Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant | 000 | 2 | NIH | 9/2/2024 | $664,838 |
| | 2024 | 2024 | MARKER THERAPEUTICS INC | 9350 KIRBY DR STE 300 | HOUSTON | TX | 77054-2528 | HARRIS | USA | R44CA295168 | A Phase 1 Study of Patient-Derived Multi-Tumor Associated Antigen Specific T Cells (MT-601) Administered to Patients with Metastatic Pancreatic Cancer following frontline FOLFIRINOX | 000 | 1 | NIH | 8/30/2024 | $674,275 |
| | 2024 | 2022 | MARKER THERAPEUTICS, INC. | 3200 SOUTHWEST FWY STE 2500 | HOUSTON | TX | 77027-7528 | HARRIS | USA | R01FD007272 | Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in AML Patients following Allogeneic Stem Cell Transplant with Minimal Residual Disease | 000 | 1 | FDA | 1/18/2024 | $0 |
| | 2024 | 2022 | MARKER THERAPEUTICS INC | 9350 KIRBY DR STE 300 | HOUSTON | TX | 77054-2528 | HARRIS | USA | R01FD007272 | Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in AML Patients following Allogeneic Stem Cell Transplant with Minimal Residual Disease | 001 | 1 | FDA | 2/21/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $664,838 ) |
| | 2023 | 2023 | MARKER THERAPEUTICS, INC. | 3200 SOUTHWEST FWY STE 2500 | HOUSTON | TX | 77027-7528 | HARRIS | USA | R44CA285177 | Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant | 000 | 1 | NIH | 8/8/2023 | $664,838 |
| | 2023 | 2022 | MARKER THERAPEUTICS, INC. | 3200 SOUTHWEST FWY STE 2500 | HOUSTON | TX | 77027-7528 | HARRIS | USA | R01FD007272 | Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in AML Patients following Allogeneic Stem Cell Transplant with Minimal Residual Disease | 000 | 1 | FDA | 6/29/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $519,750 ) |
| | 2022 | 2022 | MARKER THERAPEUTICS, INC. | 3200 SOUTHWEST FWY STE 2500 | HOUSTON | TX | 77027-7528 | HARRIS | USA | R01FD007272 | Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in AML Patients following Allogeneic Stem Cell Transplant with Minimal Residual Disease | 000 | 1 | FDA | 9/8/2022 | $519,750 |
|
|
